Previous 10 | Next 10 |
The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this Read more ...
Emergent BioSolutions, Inc. (EBS) Q2 2019 Results Earnings Conference Call August 01, 2019, 05:00 PM ET Company Participants Bob Burrows - VP-IR Bob Kramer - President and CEO Rich Lindahl - CFO Doug White - SVP, Devices Business Unit Head Conference Call Participants Bra...
Emergent Biosolutions (NYSE: EBS ): Q2 Non-GAAP EPS of -$0.12 beats by $0.03 ; GAAP EPS of -$0.18 misses by $0.03 . More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Reaffirms full year 2019 financial forecast and operational goals Provides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the second quarter and six months ended June...
GAITHERSBURG, Md., July 30, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsor...
GAITHERSBURG, Md., July 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2019, recent business developments, revenue guidance for t...
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the company for its oral cholera vaccine, Vaxchora ® (Cholera Vaccine, Li...
Emergent BioSolutions (NYSE: EBS ) has received a contract award of ~$535M over 10 years for the continued supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS) in support of smallpox preparedness. More news on: Emergent BioSolutions Inc....
GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $535 m...
GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif ® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member States, i...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...